GHK-Cu: benefits, side effects and what the research shows

GHK is a tripeptide made of glycine, histidine and lysine. In 1973 Loren Pickart and M. M. Thaler reported a tripeptide in human serum that prolonged the survival of normal liver cells and stimulated the growth of liver tumour cells in culture ^[1]. In 1980 Pickart and colleagues reported in Nature that the peptide co-purified with roughly equal amounts of copper, readily formed a complex with copper(II) ions and increased copper uptake into cultured cells, which led them to propose that it acts as a copper carrier ^[2]. The copper-bound form is known as GHK-Cu.

GHK-Cu is sold in two quite different markets. As a cosmetic ingredient, listed under the name copper tripeptide-1, it appears in creams and serums. As a “research peptide”, it is sold in vials for injection, which is the use regulators have raised concerns about ^[14]. The evidence for these two uses is different, and this page separates them.

It is sometimes grouped with other peptides marketed for repair or appearance, such as BPC-157 and TB-500, but it is chemically unrelated to both. For how the research peptide market works in general, see what research peptides are.

GHK occurs naturally in the body. Reviews report that it is present in plasma, saliva and urine and that plasma levels fall with age, from an average of about 200 ng/mL at age 20 to about 80 ng/mL by age 60 ^{[20] [21]}. That decline is the basis of much of the anti-ageing marketing, but a falling blood level does not by itself show that adding GHK-Cu back, on the skin or by injection, reverses any sign of ageing.

The most studied mechanism is an effect on the connective-tissue matrix. In a 1988 study using fibroblast cultures, GHK-Cu stimulated collagen synthesis starting at concentrations between 10⁻¹² and 10⁻¹¹ M, with a maximum at 10⁻⁹ M, independent of any change in cell number. The authors noted that the GHK sequence occurs within type I collagen and suggested it may be released at wound sites ^[3].

A second line of work uses gene-expression data. In a 2012 study of lung tissue from smokers with COPD, researchers used the Connectivity Map database to identify GHK as a compound whose gene-expression effects ran opposite to the signature of emphysema. In the laboratory, GHK applied to lung fibroblasts from people with COPD restored their ability to contract and remodel collagen ^[9]. Pickart and a co-author later reviewed such gene data and argued that GHK regulates many pathways involved in repair and protection ^[10]; this review is by the peptide’s discoverer and is a summary of largely preclinical findings rather than new clinical evidence.

Reviews by the same group describe GHK as stimulating both the build-up and the breakdown of collagen and glycosaminoglycans, adjusting the balance between tissue-degrading enzymes (metalloproteinases) and their inhibitors, and attracting immune and blood-vessel cells to an injury ^[20]. These are laboratory and animal observations. They explain why GHK-Cu is studied for skin and wound repair, but they do not measure what a cream or an injection does in a person.

The claimed benefits of GHK-Cu fall into four groups: wound healing, skin ageing, hair growth and a broad “anti-ageing” effect based on gene data. The evidence is strongest, though still limited, for topical use on wounds. For skin appearance there are laboratory studies and very few controlled human trials. For hair there is one small trial of a combination product and some cell work on a related peptide. For injected GHK-Cu there are no human efficacy trials at all.

A 2026 narrative review in the American Journal of Sports Medicine, written for orthopaedic surgeons, reached the same conclusion for musculoskeletal use: GHK-Cu showed promise in wound healing and anti-inflammatory models, but no clinical data support its use for musculoskeletal conditions, and dosing, frequency and duration are unknown ^[22]. The sections below take each claimed benefit in turn.

In a 2003 veterinary surgery study, 24 rats had full-thickness wounds created in an area with deliberately reduced blood supply. Wounds treated daily with a 2% GHK-Cu gel shrank by 64.5% of their starting area by day 13, compared with 45.6% for the gel base alone and 28.2% for untreated wounds, and had lower levels of the inflammatory marker TNF-alpha and of the tissue-degrading enzymes MMP-2 and MMP-9 ^[4].

Not all animal results are positive. A 2013 study of skin flaps in rats that had previously received radiation found that twice-daily GHK-Cu gel made no difference to flap ischaemia, blood-vessel number or area, or VEGF expression compared with a control ointment ^[5].

Most of the popular interest in GHK-Cu relates to skin ageing. A 2025 review of topical GHK as an anti-wrinkle ingredient concluded that cell studies support its effect on collagen and glycosaminoglycan production, but it described “a surprising absence of clinical studies” of GHK-Cu and its palmitoylated form, and noted that getting a water-loving peptide through the skin is a practical challenge ^[11].

A 2026 systematic review in Aesthetic Surgery Journal found 20 eligible studies of GHK-Cu used alone for aesthetic purposes, of which 18 were preclinical and only two were randomised controlled trials. It judged that GHK-Cu has a reasonable biological basis but that the clinical evidence was limited by small numbers and inconsistent methods ^[12].

Much of the rest of the skin evidence is laboratory work on formulations. A 2023 study combined GHK-Cu with low-molecular-weight hyaluronic acid and reported increased collagen IV in fibroblast cultures and in samples of skin kept alive outside the body ^[26]. Another 2023 study loaded GHK-Cu into liposomes and found that, in a test-tube assay, it inhibited elastase, an enzyme that breaks down elastin, by about 49%, while having no significant effect on tyrosinase, the enzyme involved in pigmentation ^[27]. Neither study measured wrinkles in people.

A frequently shared Korean report described one 59-year-old man treated weekly for 12 weeks with a skin-resurfacing device and a solution that contained copper-GHK together with hyaluronic acid, a plant extract, tranexamic acid and beta-glucan. Photographs showed fewer wrinkles and biopsies showed more collagen ^[28]. It is a single case with a multi-ingredient product and no comparison group, so it cannot show what GHK-Cu contributed.

For hair, the one controlled human trial we found did not test GHK-Cu alone. In a 2016 Korean study, 45 men with pattern hair loss applied a complex of 5-aminolevulinic acid and GHK peptide (at two strengths) or placebo daily for six months. Both active groups had larger increases in hair count than placebo, with no difference in hair length or thickness and no adverse events reported ^[8]. Because the product combined two substances, the result cannot be attributed to GHK alone.

The laboratory evidence usually quoted for hair comes from a closely related peptide. In a 2007 study from Seoul National University, AHK-Cu (alanine in place of glycine) at 10⁻¹² to 10⁻⁹ M lengthened human hair follicles kept in culture and increased the growth of dermal papilla cells, the cells that control the hair cycle, while reducing markers of their programmed cell death ^[15]. This was not a study of GHK-Cu, and it was not a study in people.

Pickart’s 2015 review lists hair follicles among the tissues whose healing GHK has been reported to accelerate ^[20]. We did not find a controlled trial of a GHK-Cu hair tonic, scalp serum or injection used on its own. Popular “GHK-Cu hair growth before and after” photographs are not a substitute for a trial. In the 2016 study, even the placebo group gained an average of 9.6 hairs over six months ^[8], which is why a comparison group matters.

We found no clinical trial of GHK-Cu for acne in PubMed. The idea usually rests on two things: its anti-inflammatory effects in laboratory models ^[20], and reports of antibacterial activity. The antibacterial study most often cited attached GHK or GHK-Cu to silver nanoparticles; the particles killed Staphylococcus aureus and Escherichia coli in the laboratory and helped infected wounds heal in animals ^[19]. Silver is itself an antibacterial agent, so the result says little about a copper peptide serum applied to spots.

In short, there is no direct evidence that GHK-Cu treats acne. GHK-Cu may still appear in skin-care products aimed at post-acne marks, but those are cosmetic products, not tested acne treatments.

AHK-Cu and GHK-Cu are both copper complexes of three-amino-acid peptides. They differ in the first amino acid: GHK starts with glycine, AHK with alanine. GHK occurs naturally in human plasma ^{[2] [21]}; we found no comparable evidence that AHK does. Both bind copper.

The evidence base is very different in size. GHK-Cu has a human diabetic ulcer trial, a small laser-resurfacing trial and a large body of cell and animal work ^{[6] [7] [12]}. AHK-Cu’s main published evidence is the 2007 hair-follicle culture study described above ^[15]. No study we found compared the two directly, in cells or in people, so claims that one is stronger than the other for hair or skin are not supported by published data.

The main clinical study of GHK-Cu is a 1994 multicentre, randomised, evaluator-blinded, placebo-controlled trial in people with diabetic foot ulcers, all of whom also received standardised wound care. Daily topical GHK-Cu gel increased median closure of plantar ulcers to 98.5%, compared with 60.8% for the gel base, and the difference was larger in ulcers bigger than 100 mm². Ulcer infections were also less common in the treated group (7% versus 34%) ^[6]. GHK-Cu has not become an approved treatment for diabetic ulcers.

In a 2006 randomised study, 13 patients who had carbon dioxide laser resurfacing around the mouth used skin-care products with or without GHK-Cu. Blinded assessment and computer analysis found no significant difference in redness, wrinkles or overall skin quality between groups, although patients using the GHK-Cu products reported higher satisfaction ^[7].

We found no published human trial of injected GHK-Cu. A 2026 Sports Medicine review of peptides marketed directly to patients, which included GHK-Cu, concluded that rigorous human safety data for such unapproved peptides are scarce ^[13].

There is no reliable answer for most uses, because the few human trials measured results at fixed points rather than tracking when changes began. The laser-resurfacing study assessed wrinkles and overall skin appearance 12 weeks after treatment and found no objective difference between groups at that point ^[7]. The hair trial measured hair counts at one, three and six months and reported its main result at six months, for a product that combined GHK with 5-aminolevulinic acid ^[8]. In the rat wound study, the difference in wound size was measured at day 13 ^[4].

The week-by-week timelines found on sales pages are not drawn from trials. GHK-Cu before and after photographs have the same weakness. In the laser study, every patient’s wrinkles and skin quality improved significantly, whether or not they used GHK-Cu ^[7]; without a comparison group, that improvement would have looked like an effect of the peptide.

Topical products are the only form with human trial data. The diabetic ulcer trial used a gel on open wounds ^[6], and the laser study used creams on freshly resurfaced skin ^[7], both situations in which the outer skin barrier is broken. On intact skin, getting GHK-Cu in is harder: it is water-soluble, and the outer layer of skin (the stratum corneum) keeps most such molecules out ^[18].

Laboratory measurements show some penetration. In a 2011 study using human skin in diffusion cells, copper applied as a 0.68% GHK-Cu solution passed through skin with the stratum corneum removed and through thin slices of whole skin, with part of it retained in the tissue ^[16]. A 2015 study found that almost no peptide or copper crossed intact human skin in nine hours, but pre-treating the skin with a microneedle array allowed measurable amounts through, without obvious irritation in animal tests ^[17]. Liposome carriers are being developed for the same reason, although a 2025 review noted that their effect on GHK-Cu delivery through skin has received little study ^[18].

A GHK-Cu peptide injection is a different product altogether. Injected GHK-Cu bypasses the skin, but there is no published human study of its absorption, blood levels, half-life or effects, and no study defines an injection site, amount or schedule. The FDA’s safety concern about compounded GHK-Cu relates specifically to injectable use ^[14]. Pre-filled “pens” sold online are not approved products either.

We found no published study of GHK-Cu taken by mouth as tablets or capsules. Copper peptide serum and cream products are sold as cosmetics. The trials above tested specific study products, not the retail serums on sale today.

Cell culture: collagen synthesis in fibroblasts responded from about 10⁻¹² M, with a maximum effect at 10⁻⁹ M ^[3]. Animal: the 2003 rat wound study applied a 2% GHK-Cu gel once daily for 13 days ^[4]; the 2013 irradiated-flap study applied GHK-Cu gel twice daily for 10 days ^[5].

Human: the diabetic ulcer trial used a daily metered application of topical GHK-Cu gel ^[6], and the laser-resurfacing study used GHK-Cu skin-care products ^[7]; the abstracts do not give a single standard concentration. No human dose for injected GHK-Cu has been established in any published trial, and none of these figures is a recommendation. The peptide calculator can convert vial contents to concentrations but does not indicate an appropriate amount.

Questions about vial arithmetic come up often, so here is the maths only. Concentration is the amount of powder divided by the volume of liquid added: 50 mg made up to 2 mL gives 25 mg/mL, and 50 mg made up to 5 mL gives 10 mg/mL. On a U-100 insulin syringe one unit is 0.01 mL, so at 10 mg/mL one unit contains 0.1 mg. Dosing charts circulating online, including charts labelled by vial size such as 50 mg or 100 mg, are not based on published human studies. Our guide to bacteriostatic water explains what the diluent is and why it matters for multi-use vials.

In the published topical studies, GHK-Cu was generally well tolerated; the hair study reported no adverse events ^[8], and the diabetic ulcer trial reported fewer infections in the treated group than with the gel base ^[6]. These trials were small and short.

Injection is a different matter. The FDA has said that compounded injectable drugs containing GHK-Cu may pose a risk of immune reactions (immunogenicity) because of aggregation and peptide-related impurities, and that human safety data are limited ^[14]. The original 1973 report also noted that the serum tripeptide stimulated the growth of liver tumour cells in culture ^[1]; the relevance of this to people is unknown, but it is one reason reviewers call for proper safety studies.

The cancer question cuts both ways in the laboratory literature. The same research group that reported tumour-cell growth in 1973 later proposed GHK as a possible treatment for metastatic colon cancer on the basis of gene-expression data ^[20]. Neither observation comes from a study in people, and we found no human data on cancer risk from repeated GHK-Cu injection.

For skin products, the microneedle study reported no obvious signs of irritation when GHK-Cu was applied after microneedle pre-treatment ^[17]. That is reassuring but limited: it was a short laboratory and animal assessment, not a long-term study of daily use on the face.

The practical risks of research-grade vials are the usual ones for unregulated peptides: wrong content, impurities and contamination, and no sterility guarantee. That is why independent testing matters; see third-party peptide testing.

GHK-Cu is often sold in pre-mixed blends. Products marketed as “GLOW” combine GHK-Cu with BPC-157 and TB-500, and “KLOW” blends add KPV. We found no published study of any of these combinations, in animals or in people, so there is no evidence about how the ingredients interact, whether their effects add up, or what amounts of each were intended. What is and is not known about these blends is set out in Glow and Klow peptide blends.

Each ingredient carries its own evidence gaps: BPC-157 and TB-500 have almost no human trial data, and neither does injected GHK-Cu ^[13]. Blending them also makes it harder to check what is in the vial, because a certificate of analysis has to identify and quantify several peptides at once. Our guide to reading a COA covers what to look for.

GHK-Cu is not approved as a medicine by the FDA, the UK’s MHRA or, as far as we are aware, any other regulator. It is widely used in cosmetics under the ingredient name copper tripeptide-1, which covers topical skin-care use only.

In the US, the FDA previously placed “GHK-Cu (for injectable routes of administration)” in category 2 of its interim compounding policy, the list of bulk substances that may present significant safety risks; the nomination was later withdrawn and the FDA now lists it among substances previously in category 2 ^[14]. GHK-Cu was not among the peptides considered at the FDA’s July 2026 compounding advisory committee meeting. For national rules on research peptides, see our legal status overview and the UK page.

In Australia, the TGA names GHK-Cu among its examples of unapproved peptide products, says such products are regulated as therapeutic goods, and says a “research use only” label does not make their supply lawful ^[23]. GHK-Cu is not named in the June 2026 Poisons Standard ^[25]. See peptide rules in Australia.

In Canada, a Health Canada advisory of April 2026 lists GHK-Cu among peptides seized as unauthorised products, states that unauthorised drug products are illegal in Canada, and says research-use-only labelling does not exempt them ^[24]. See peptide rules in Canada.

We found no published human pharmacokinetic study of GHK-Cu given by injection, so there is no established half-life in people. Figures quoted on sales pages are not backed by a human study we could find.

Research-grade GHK-Cu is supplied as a powder in sealed vials. Peptides are generally stored cold, dry and away from light, and reconstituted solutions are refrigerated and used within a limited period. Our guide to storing peptides covers the general principles.

Research GHK-Cu is not regulated like a medicine, so batch testing is the main safeguard. Compare prices, read how to read a COA, and see which vendors publish third-party tested results.

Prices and availability differ by country. You can compare GHK-Cu UK prices, US prices and GHK-Cu Australia prices from the suppliers we track. Listing on PepFinder does not mean a product is legal to buy for human use in your country. Our guide on how to spot a fake peptide supplier lists warning signs, and our methodology explains how we score vendors.